Affibody Medical Partnering

Affibody has a proven track record of developing candidate drugs targeting severe diseases based on its proprietary technology platform. To fully unlock the potential of the platform, Affibody seeks partnerships with leading companies that excel in their therapeutic areas.

Complement mediated diseases

Affibody’s partner Rallybio is developing the drug candidate RLYB116 which acts by inhibiting the activation of complement factor 5 (C5) in the complement cascade, which is part of the immune system.

Respiratory diseases

Affibody is collaborating with Chiesi to discover and develop novel Affibody® molecules as innovative treatments for respiratory diseases.

Fibrotic diseases

Affibody’s partner Antaros is developing an Affibody®-based PET tracer, ATH001, to probe the presence of platelet-related growth factor receptor beta (PDGFRβ), which is a marker of ongoing fibrogenesis in tissue.

To fully unlock the potential of the platform, Affibody seeks partnerships with leading companies that excel in their therapeutic areas

Our partners

Rallybio

Affibody’s licensee Rallybio for RLYB116 is a US-based biotechnology company founded by industry veterans from the global biopharma company Alexion. The company develops therapies aimed at severe and rare diseases in hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. RLYB116 is aimed at treating rare complement mediated diseases.

Chiesi Group

In 2023, Affibody and Chiesi partnered for the development of innovative treatments for respiratory diseases. The agreement expands Chiesi’s comprehensive R&D program in respiratory diseases with high unmet medical needs. Affibody has retained the option to co-promote in the Nordic region.

Antaros

In 2021, Affibody and Antaros entered into a license agreement to develop novel PET imaging tracers to support drug development decisions, with an initial focus on unmet needs in inflammation, fibrosis, and immunology. In 2023, Antaros announced that they are collaborating with Takeda to evaluate ATH001 in fibrosis/fibrogenesis linked to metabolic dysfunction-associated steatohepatitis (MASH, previously called non-alcoholic steatohepatitis or NASH) and two additional fibrotic indications.

Partnering Contacts

We believe that external collaborations are essential for our success.

Contact us